Cholangiocarcinoma is among the malignancies with the poorest prognoses. To advance our understanding of its pathophysiology, more physiologically relevant in vitro platforms are essential. Conventional 2D cell cultures often fail to recapitulate the native tissue architecture, leading to loss of cell polarity and altered cell-ECM interactions. While animal models capture systemic complexity, they are subject to cross-species differences and raise ethical considerations. Cholangiocarcinoma organoids, as 3D in vitro models, preserve key characteristics of the original tumor, including cellular heterogeneity, glandular architecture, stem cell populations, and molecular profiles. They thus provide a stable, scalable, and highly reproducible platform that bridges the gap between traditional 2D cultures and complex in vivo models, enabling more accurate and translational biomedical research.
Drug Screening and Sensitivity Testing
Cholangiocarcinoma organoids are increasingly used for high-throughput drug screening. They enable the evaluation of targeted agents and combination therapies with respect to efficacy, toxicity, and mechanism of action, thereby enabling tailored therapy strategies based on specific drug responses.
Research on Cellular Metabolism in Cholangiocarcinoma
These organoid models offer an ideal system for examining mitochondrial function and metabolic reprogramming in cholangiocarcinoma. They help elucidate how altered energy metabolism promotes tumor growth and drug resistance, thereby revealing new therapeutic strategies from a metabolic perspective.
Investigation of Tumorigenesis and Progression
Organoids provide a powerful platform to study tumor initiation, progression, and metastasis. They enable controlled investigation of driver mutations, tumor-stroma interactions, and the tumor microenvironment, supporting the discovery of novel therapeutic targets and biomarkers.
Leveraging extensive expertise in 3D cancer model biology and a state-of-the-art platform, Alfa Cytology delivers robust, data-driven cholangiocarcinoma organoid development services. Our commitment to rigorous quality control, deep phenotypic and genotypic validation, and adaptable protocol design ensures the generation of highly reliable and translationally relevant models for both academic research and pharmaceutical development.
Alfa Cytology's service portfolio encompasses the development of organoid models for the major subtypes of cholangiocarcinoma. We work with diverse starting materials such as primary tumor tissues, adjacent normal tissues, and iPSCs to generate models that address the distinct biological and contextual differences of each subtype.
By Types
Beyond model development, we offer a comprehensive suite of research services utilizing established cholangiocarcinoma organoids. These include organoid model-based basic research services, such as genetic manipulation, co-culture systems, and invasion assays, as well as organoid model-based preclinical research services encompassing compound efficacy testing, pharmacokinetic profiling, and biomarker discovery to accelerate therapeutic development.
Alfa Cytology established an organoid model of intrahepatic cholangiocarcinoma (ICC) through the enzymatic digestion of primary tumor tissue and subsequent 3D cultivation in a defined extracellular matrix and optimized medium. Utilizing this physiologically relevant platform, we evaluated the efficacy of two novel anticancer peptides (ACPs). Therapy with these agents induced significant cytotoxicity, characterized by a marked increase in extracellular nucleic acids and proteins, indicative of membrane disruption. Furthermore, the peptides demonstrated a potent ability to activate apoptotic pathways. These results validate our ICC organoid platform as a highly reliable and translational tool for modeling tumor biology and performing predictive preclinical drug screening.
Fig.1 Development and characterization of a robust ICC organoid. (A) Schematic of the ICC organoid generation workflow. (B) Evaluation of ACP efficacy using the ICC organoid platform. Data are presented as mean ± SEM (n=5; ***p < 0.001, **p < 0.01).
As a dedicated partner for the development of cholangiocarcinoma organoids and for the applications, Alfa Cytology offers an integrated and comprehensive service for the advancement of cholangiocarcinoma research. Our integrated platform and specialized expertise provide a resource for advancing cholangiocarcinoma research through customizable organoid technologies. For detailed project discussions or to receive a customized proposal, please contact our scientific team to explore how our cholangiocarcinoma organoid development services can support your specific program requirements.
Reference
For research use only.
Alfa Cytology is a preclinical research service provider specializing in tumor organoid development. We provide one-stop services that include tailored 3D cancer models, organoid-based research services, and related products to accelerate the discovery and development of cancer therapeutics.
Copyright © 2026 Alfa Cytology. All rights reserved.
